acarbose/hepatitis

Lyen an sove nan clipboard la

Chwazi kalite sòt

14 rezilta yo

[Acarbose-induced acute hepatitis. Report of two events in the same patient].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A 57-year-old woman with non-insulin-dependent diabetes mellitus and inadequate glycemic control was prescribed acarbose (100 mg 3 times daily). Two months later she presented with acute hepatitis (ALT 2,300 IU/l). Other causes of liver damage were excluded. Three months after acarbose had been

Acarbose-induced acute hepatitis.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

[Acute hepatitis induced by acarbose].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Acarbose-induced liver injury in an anti-hepatitis C virus positive patient.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

[Acarbose-induced acute hepatitis].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

[Acarbose and propofol: a dangerous combination?].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Hepatotoxicity is a rare complication following the use of propofol and can be potentially serious if an early diagnosis is not made. Propofol is being increasingly used in daily practice, not only in surgery, but also in outpatient sedation procedures, such as endoscopy. Acarbose is a well-known

[Comorbidities and concomitant medication use in adult patients with chronic hepatitis C: a descriptive epidemiological analysis].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Objective: To analyze the comorbidity and concomitant medications use in adult patients with chronic hepatitis C. Methods: A descriptive epidemiological methods was carried out in adult patients with chronic hepatitis C and data from 2013 to 2015 were accessed through the China Medical Insurance

Safe and effective treatment of diabetes mellitus associated with chronic liver diseases with an alpha-glucosidase inhibitor, acarbose.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Glucose intolerance and diabetes mellitus are both prevalent in patients with chronic liver diseases. We examined the efficacy and systemic safety of therapy with an alpha-glucosidase inhibitor, acarbose, in diabetes mellitus associated with chronic liver diseases. Twenty patients with chronic

A pilot study of add-on oral hypoglycemic agents in treatment-naïve genotype-1 chronic hepatitis C patients receiving peginterferon alfa-2b plus ribavirin.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

OBJECTIVE Insulin resistance (IR) affects sustained virological response (SVR) to peginterferon alfa plus ribavirin (PR) in patients with chronic hepatitis C (CHC). Whether add-on oral hypoglycemic agents (OHAs) to PR improve SVR remains unclear; therefore, we conducted a prospective, randomized

α-Glucosidase inhibition, 15-lipoxygenase inhibition, and brine shrimp toxicity of extracts and isolated compounds from Terminalia macroptera leaves.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

BACKGROUND Terminalia macroptera Guill. & Perr. (Combretaceae), a tree that grows in West Africa, has been used in traditional medicine against a variety of diseases such as hepatitis, gonorrhea, skin diseases, and diabetes. OBJECTIVE To investigate enzyme inhibitory activity against α-glucosidase

Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipid-lowering agents, psychotropic drugs.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Hepatotoxic adverse drug reactions have contributed to the decline of many promising therapies, even among mainstream medication classes (bromfenac and troglitazone are recent examples). The spectrum of nonsteroidal anti-inflammatory drug-related liver toxicity continues to expand, with reports in

[Hepatotoxicity of medications].

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

A TIMELY TOPIC: Liver toxicity remains a common problem despite adequate information for physicians and drug watch programs. The number of recent publications reporting severe drug-induced liver disease emphasizes the need for prudence. ACUTE AND CHRONIC HEPATOTOXICITY: Cases of acute drug-induced

Potential Antidiabetic Activity of Extracts and Isolated Compound from Adenosma bracteosum (Bonati).

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

Adenosma bracteosum Bonati. (A. bracteosum) has been used in traditional and modern medicine in Vietnam for curing hepatitis. In this study, ethanol and aqueous extracts of A. bracteosum were evaluated for their α-glucosidase inhibitory activities and anti-hyperglycemic effects

Hepatotoxicity caused by both tacrolimus and cyclosporine after living donor liver transplantation.

Se sèlman itilizatè ki anrejistre yo ki ka tradwi atik yo

We present a case report of a posttransplant patient who had hepatotoxicity due to both tacrolimus and cyclosporine and cholestatic jaundice due to tacrolimus. The patient did not show sustained improvement in enzyme and bilirubin abnormalities after an initial change from tacrolimus to cyclosporine

Antre nan paj
facebook nou an

Herbal & Natural Medicine

Baz done ki pi konplè remèd fèy medsin te apiye nan syans

Travay nan 55 lang
Geri èrbal te apiye nan syans
Remèd fèy rekonesans pa imaj
Kat entèaktif GPS - tag zèb sou kote (vini byento)
Li piblikasyon syantifik ki gen rapò ak rechèch ou an
Search remèd fèy medsin pa efè yo
Izeganize enterè ou yo ak rete kanpe fè dat ak rechèch la nouvèl, esè klinik ak rive

Tape yon sentòm oswa yon maladi epi li sou remèd fèy ki ta ka ede, tape yon zèb ak wè maladi ak sentòm li itilize kont.
* Tout enfòmasyon baze sou rechèch syantifik pibliye